- Home
- COYA vs OCCI Comparison
COYA vs OCCI Comparison
Compare COYA & OCCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COYA
- OCCI
- Stock Information
- Founded
- COYA 2020
- OCCI N/A
- Country
- COYA United States
- OCCI United States
- Employees
- COYA N/A
- OCCI N/A
- Industry
- COYA Biotechnology: Pharmaceutical Preparations
- OCCI Trusts Except Educational Religious and Charitable
- Sector
- COYA Health Care
- OCCI Finance
- Exchange
- COYA Nasdaq
- OCCI Nasdaq
- Market Cap
- COYA 104.3M
- OCCI 117.5M
- IPO Year
- COYA 2022
- OCCI N/A
- Fundamental
- Price
- COYA $5.74
- OCCI $7.27
- Analyst Decision
- COYA Strong Buy
- OCCI
- Analyst Count
- COYA 4
- OCCI 0
- Target Price
- COYA $16.25
- OCCI N/A
- AVG Volume (30 Days)
- COYA 70.0K
- OCCI 115.8K
- Earning Date
- COYA 11-06-2024
- OCCI 12-11-2023
- Dividend Yield
- COYA N/A
- OCCI 24.32%
- EPS Growth
- COYA N/A
- OCCI N/A
- EPS
- COYA N/A
- OCCI N/A
- Revenue
- COYA $9,554,315.00
- OCCI N/A
- Revenue This Year
- COYA N/A
- OCCI N/A
- Revenue Next Year
- COYA $87.80
- OCCI $10.19
- P/E Ratio
- COYA N/A
- OCCI N/A
- Revenue Growth
- COYA N/A
- OCCI N/A
- 52 Week Low
- COYA $4.75
- OCCI $5.47
- 52 Week High
- COYA $10.69
- OCCI $10.15
- Technical
- Relative Strength Index (RSI)
- COYA 36.62
- OCCI 59.21
- Support Level
- COYA $5.40
- OCCI $7.35
- Resistance Level
- COYA $6.44
- OCCI $7.58
- Average True Range (ATR)
- COYA 0.35
- OCCI 0.10
- MACD
- COYA -0.02
- OCCI 0.02
- Stochastic Oscillator
- COYA 17.78
- OCCI 70.32
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
About OCCI OFS Credit Company Inc.
OFS Credit Co Inc is a non-diversified, closed-end management investment company. Its investment objective is to generate current income, with a secondary objective to generate capital appreciation. The company invests in floating rate credit instruments and other structured credit investments, including; collateralized loan obligation (CLO) debt and subordinated (i.e., residual or equity) securities; traditional corporate credit investments, including leveraged loans and high yield bonds; opportunistic credit investments, including stressed and distressed credit situations and long/short credit investments; and other credit-related instruments.